Skip to main content
Article thumbnail
Location of Repository

Comparative Transcriptional Network Modeling of Three PPAR-α/γ Co-Agonists Reveals Distinct Metabolic Gene Signatures in Primary Human Hepatocytes

By Renée Deehan, Pia Maerz-Weiss, Natalie L. Catlett, Guido Steiner, Ben Wong, Matthew B. Wright, Gil Blander, Keith O. Elliston, William Ladd, Maria Bobadilla, Jacques Mizrahi, Carolina Haefliger and Alan Edgar
Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2011). A computable cellular stress network model for non-diseased pulmonary and cardiovascular tissue.
  2. (2007). A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus.
  3. (2004). A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.
  4. (2012). A study with aleglitazar in patients with a recent acute coronary syndrome and type 2 diabetes mellitus. Available: http://clinicaltrials. gov/ct2/show/NCT01042769. Accessed
  5. (2009). Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.
  6. (2002). Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase.
  7. (2007). Angptl4 upregulates cholesterol synthesis in liver via inhibition of LPL- and HLdependent hepatic cholesterol uptake.
  8. (2010). Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5.
  9. (2005). Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants.
  10. (2003). Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators.
  11. (2009). Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by upregulating peroxisome proliferator-activated receptor-alpha.
  12. (2004). Bioconductor: open software development for computational biology and bioinformatics.
  13. (2010). Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693.
  14. (2001). Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer.
  15. (2000). Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene.
  16. (2011). Comparative gene expression profiles induced by PPARgamma and PPARalpha/gamma agonists in human hepatocytes.
  17. (2008). Consequences of lipid droplet coat protein downregulation in liver cells: abnormal lipid droplet metabolism and induction of insulin resistance.
  18. (2011). Construction of a computable cell proliferation network focused on non-diseased lung cells.
  19. (2000). Controlling the false discovery rate: A practical and powerful approach to multiple testing.
  20. (2005). Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
  21. (2009). Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review.
  22. (2009). Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.
  23. (2011). Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor alpha/gamma agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome.
  24. (2007). Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulintreated patients with type 2 diabetes. Diab Vasc Dis Res 4: 214–221. Unique Gene Signature Profile of PPAR-a/c Agonists
  25. (2007). Emerging role of Nrf2 in protecting against hepatic and gastrointestinal disease.
  26. (2003). Exploration, normalization, and summaries of high density oligonucleotide array probe level data.
  27. (1987). Fibric acids: effects on lipids and lipoprotein metabolism.
  28. (2012). Genes associated with intestinal permeability in ulcerative colitis: Changes in expression following infliximab therapy. Inflamm Bowel Dis.
  29. (2008). HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis.
  30. (2005). Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study.
  31. (2004). Linear models and empirical bayes methods for assessing differential expression in microarray experiments.
  32. (2001). Peroxisome proliferator-activated receptors in inflammation control.
  33. (2007). Persson A
  34. (2004). Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans.
  35. (2003). Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study.
  36. (2002). Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis.
  37. (2007). PPARalpha and dyslipidemia.
  38. (2009). PTEN and the PI3-kinase pathway in cancer.
  39. Radhakrishnan SK (2005) Lost in transcription: p21 repression, mechanisms, and consequences.
  40. (2009). Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans.
  41. (2007). Regulation of Triglyceride Metabolism. III. Emerging role of lipid droplet protein ADFP in health and disease.
  42. (2004). Rosiglitazone induction of Insig-1 in white adipose tissue reveals a novel interplay of peroxisome proliferator-activated receptor gamma and sterol regulatory element-binding protein in the regulation of adipogenesis.
  43. (2009). SIRT1 promotes differentiation of normal human keratinocytes.
  44. Sladek TL (2010) E2F-1 has dual roles depending on the cell cycle.
  45. (2009). Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo.
  46. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.
  47. (2007). The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response.
  48. (2010). The role of hypoxia in 2-butoxyethanol-induced hemangiosarcoma.
  49. (1997). The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor.
  50. (2005). Therapeutic roles of peroxisome proliferatoractivated receptor agonists.
  51. (2006). Transcription factor YY1: structure, function, and therapeutic implications in cancer biology.
  52. (1997). Tsubura A

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.